A-366
CAS No. 1527503-11-2
A-366 ( A366 )
产品货号. M12140 CAS No. 1527503-11-2
A-366 是一种有效的、高选择性的组蛋白甲基转移酶 G9a/GLP 抑制剂,IC50 为 3/38 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥348 | 有现货 |
|
| 5MG | ¥551 | 有现货 |
|
| 10MG | ¥745 | 有现货 |
|
| 25MG | ¥1774 | 有现货 |
|
| 50MG | ¥3062 | 有现货 |
|
| 100MG | ¥4520 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称A-366
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述A-366 是一种有效的、高选择性的组蛋白甲基转移酶 G9a/GLP 抑制剂,IC50 为 3/38 nM。
-
产品描述A-366 is a potent, highly selective inhibitor of histone methyltransferase G9a/GLP with IC50 of 3/38 nM, >1,000-fold selectivity for G9a over 21 other methyltransferases; effects a clear reduction in H3K9 methylation in cells, shows significantly less cytotoxic effects on the growth of tumor cell lines compared to other known G9a/GLP small molecule inhibitors despite equivalent cellular activity on methylation of H3K9me2 (H3K9me2 cellular EC50=0.3 uM); induces differentiation and affects viability in MV4;11 cells, demonstrates growth inhibition in vivo consistent with the profile of H3K9me2 reduction in flank xenograft leukemia model.
-
体外实验A-366 (0.01-10 μM; 14 days) induces differentiation and affects viability in MV4;11 cells.A-366 (0.3-3 μM; 72 hours) reduces the total levels of H3K9me2 in a time and concentration dependent manner with a cellular EC50 of ~300 nM in PC-3 prostate adenocarcinoma cells. A-366 (0.01-10 μM; 4 days; HL-60 cells) results in a dose-dependent differentiation and a corresponding decrease in proliferation. DNA content analysis of A-366-treated HL-60 cells showed an accumulation of cells in G1 consistent with cytostasis. Cell Viability AssayCell Line:MV4;11 cells Concentration:0.01-10 μM Incubation Time:14 days Result:Resulted in inhibited proliferation and a decrease in viability corresponding to the dose response observed for CD11b staining.
-
体内实验A-366 (30 mg/kg; osmotic mini-pump; daily for 14 days) treatment of MV4;11 xenografts elicits growth inhibition. Animal Model:6-8 week old SCID-beige female mice (MV4;11 xenografts)Dosage:30 mg/kg Administration:By osmotic mini-pump; daily for 14 days Result:A modest 45% tumor growth inhibition resulting from A-366 treatment in this model.
-
同义词A366
-
通路Chromatin/Epigenetic
-
靶点HMTase
-
受体G9a/GLP
-
研究领域Other Indications
-
适应症——
化学信息
-
CAS Number1527503-11-2
-
分子量329.4366
-
分子式C19H27N3O2
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESNC(C12CCC1)=NC3=C2C=C(OC)C(OCCCN4CCCC4)=C3
-
化学全称Spiro[cyclobutane-1,3'-[3H]indol]-2'-amine, 5'-methoxy-6'-[3-(1-pyrrolidinyl)propoxy]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sweis RF, et al. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9.
2. Pappano WN, et al. PLoS One. 2015 Jul 6;10(7):e0131716.
3. Agarwal P, et al. Cancer Lett. 2016 Oct 1;380(2):467-75.
021-51111890
购物车()
sales@molnova.cn

